Rho kinase inhibition in Amyotrophic Lateral Sclerosis - Case Study

REAL is a phase 2a open-label study to assess preliminary safety, tolerability, and effect on clinical outcomes as well as neurodegeneration biomarkers of BRAVYL in patients with ALS.  

The study will enroll approximately 20 patients, all of whom will be treated with BRAVYL for 24 weeks.